文献速递免疫规划慢病防控与筛查

澳大利亚新宫颈筛查计划中116052名女性的年龄特异性HPV感染率:监测疫苗影响的新工具

Age-specific HPV prevalence among 116,052 women in Australia's renewed cervical screening program: A new tool for monitoring vaccine impact.
PubMed 文献 · Vaccine · 2018-12-11

该研究利用澳大利亚维多利亚州大型筛查实验室在项目前7个月的数据,对25-74岁女性初级筛查样本进行致癌型HPV检测。在116052份样本中,致癌型HPV总检出率为9.25%,其中HPV16/18阳性率为2.14%,非16/18型阳性率为7.12%。HPV感染率在25-29岁达峰后随年龄下降,但主要由非16/18型驱动;HPV16/18阳性率在各年龄组保持低而平稳,与疫苗前流行病学特征不同。

要点

  • 致癌型HPV总检出率为9.25%,HPV16/18阳性率为2.14%。
  • HPV感染率25-29岁达峰后下降,主要由非16/18型驱动。
  • HPV16/18阳性率各年龄组低而平稳,提示疫苗影响。

核心结论

  • 基于HPV的宫颈筛查可精确监测HPV感染率,为评估疫苗影响提供被动监测工具。

研究设计与样本

  • 研究分析了澳大利亚维多利亚州大型筛查实验室在项目前7个月收集的116052份25-74岁女性初级筛查样本。

主要发现

  • 9.25%(95%CI: 9.09-9.42%)的样本检测到致癌型HPV。
  • 2.14%(95%CI: 2.05-2.22%)的样本为HPV16/18阳性。
  • 7.12%(95%CI: 6.97-7.27%)的样本仅非16/18型HPV阳性。
  • HPV感染率在25-29岁达峰后随年龄下降,但主要由非16/18型驱动。
  • HPV16/18阳性率各年龄组低而平稳,与疫苗前年轻女性高峰的流行病学不同。

临床怎么用

  • 利用常规HPV筛查数据可监测疫苗对感染率的影响,辅助评估免疫规划效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Australia's transition to primary human papillomavirus (HPV) based cervical screening, has for the first time, provided a passive mechanism for monitoring the impact of vaccination on infection prevalence among women attending screening. We assessed oncogenic HPV prevalence by single year of age in the first 7 months of the program, using data collected from a large screening laboratory in Victoria, Australia, which is routinely screening using cobas 4800, cobas 6800 and Seegene assays. Among 116,052 primary screening samples from women aged 25-74, 9.25% (95%CI: 9.09-9.42%) had oncogenic HPV detected: 2.14% (95%CI: 2.05-2.22%) were 16/18 positive and 7.12% (95%CI: 6.97-7.27%) were positive for only non-16/18 HPV. Prevalence peaked at age 25-29 then decreased with age, but this was driven by non-16/18 types. HPV16/18 prevalence remained low and flat across ages, contrasting with pre-vaccination epidemiology when HPV16/18 peaked in young women. HPV-based screening can precisely monitor HPV prevalence.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Brotherton JM, Hawkes D, Sultana F, et al. Age-specific HPV prevalence among 116,052 women in Australia's renewed cervical screening program: A new tool for monitoring vaccine impact. Vaccine. 2018. PMID: 30551987. doi:10.1016/j.vaccine.2018.11.075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。